---
document_datetime: 2024-11-27 14:58:53
document_pages: 54
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/exforge-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: exforge-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 96.6126694
conversion_datetime: 2025-12-20 15:22:32.661185
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Exforge

Proceduralstepstakenandscientificinformationaftertheauthorisation

| Application number   | Scope                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued2 / amended on   | Product Information affected3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| IG/1804              | B.II.b.2.c.1-Change to importer,batch release arrangements andquality controltestingof theFP- Replacementoradditionofamanufacturer responsibleforimportation and/orbatchrelease- Not includingbatch control/testing | 21/11/2024                          |                                            | Annex II and PL                 |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3 SmPC (Summary of Product Characteristics), Annex I, Labelling, PL (Package Leaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g. summary of product characteristics, annexII, labelling,package leaflet).The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a)of Regulation(Eu)No.712/2012, or within one year for other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | B.Ill.1.a.2-Submissionofanew/updatedor deletion of Ph. Eur. Certificate of Suitability to the relevant Ph.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                        | 28/08/2024   | n/a   |             | IG/1784   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------|-----------|
| IG/1763 | A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                  | 04/07/2024   | n/a   |             |           |
| IG/1708 | B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability to the relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                         | 08/04/2024   | n/a   |             |           |
|         | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                          | 25/01/2024   |       | SmPC and PL | WS/2610   |
|         | This was an applicationfor a group of variations. A.4-Administrativechange-Changeinthename and/oraddressofamanufactureroranASMFholder or supplier of the AS, starting material, reagent or intermediateused in themanufactureof theASor manufacturerofanovelexcipient A.4-Administrative change-Changein thename and/or address of a manufacturer or an ASMF holder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturerofanovelexcipient | 14/09/2023   | n/a   |             | IG/1666/G |

<div style=\"page-break-after: always\"></div>

| IG/1644/G   | This was an application for a group of variations. A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrativechange-Deletionof manufacturingsites                                                                                                                                                                                                                                                          | 08/08/2023   | n/a   |                                                                                                                                                                                                                                                                                                     |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1637     | B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                            | 19/07/2023   | n/a   |                                                                                                                                                                                                                                                                                                     |
|             | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change inthemanufacturingprocess | 02/03/2023   | n/a   | WS/2363/G B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change inthemanufacturingprocess B.II.b.4.a -Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | in the manufacturing process B.II.b.4.a -Change in the batch size (including batch sizeranges)of the finishedproduct-Up to10-fold comparedtotheoriginallyapprovedbatchsize B.II.b.4.a-Change in the batch size(including batch size ranges) of the finished product -Up to 10-fold comparedtotheoriginallyapprovedbatchsize                                                                                                  |            |            |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1598/G | Thiswas an applicationfor a group of variations. A.7-Administrativechange-Deletionof manufacturingsites A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrative change-Deletion of manufacturing sites A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                          | 28/02/2023 | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| WS/2337/G | This was an application for a group of variations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. C.I.z-Changes(Safety/Efficacy)ofHumanand VeterinaryMedicinalProducts-Othervariation C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Implementation of wording agreed by the competent authority | 10/11/2022 | 15/11/2023 | SmPC and Annex II | C.I.z-To update section4.9of theSmPC,toimplement thewordingrelatedtotheriskofnon-cardiogenic pulmonary oedema in amlodipine overdose. C.I.11.a-To update Annex II to reflect the fulfilment of ConditionB,assetoutbytheCommissionDecisionasan outcomeoftheassessmentfortheimpactoftheArticle 5(3)scientificopinion onnitrosaminesinhumanmedicinal products on the opinion adopted pursuant to Article 31 of Directive 2001/83/EC for angiotensin-II-receptor antagonists (sartans) containing a tetrazole group. |

<div style=\"page-break-after: always\"></div>

| WS/2278/G   | Thiswas an applicationfor agroupofvariations following aworksharingprocedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.III.1.a.3-Submission of a new/updated or deletion ofPh.Eur.Certificate ofSuitability to the relevantPh.Eur.Monograph-New certificate from a new manufacturer (replacement or addition) B.I.a.1.f -Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place                                                                                                                      | 27/10/2022   | n/a   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| WS/2256/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation(EC) No 1234/2008. B.II1.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificate of Suitability tothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwithits corresponding test method B.I.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure | 02/06/2022   | n/a   |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.2.a -Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate- Other changestoatestprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.f-Changein themanufacturerofASorofa startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacement or additionofasitewhere batchcontrol/testingtakesplace   |            |     |                                |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------|
| PSUSA/10344 /202106 | PeriodicSafetyUpdateEUSingleassessment- amlodipine / valsartan, amlodipine / hydrochlorothiazide/valsartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/02/2022 | n/a | PRACRecommendation-maintenance |
| IG/1439/G           | Thiswasanapplicationforagroupofvariations. B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer A.4-Administrativechange-Changeinthename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor                                                                                                                                                                                                                                                                                                                                                                                                           | 15/10/2021 | n/a |                                |

<div style=\"page-break-after: always\"></div>

|           | intermediateusedin themanufactureof theASor manufacturerofanovelexcipient                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                 |                                    |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------------|
| IG/1438/G | This was an application for a group of variations. A.7-Administrativechange-Deletionof manufacturing sites A.5.b-Administrative change-Change in the name and/oraddressof amanufacturer/importerof the finishedproduct,including quality control sites (excluding manufacturer for batch release) B.11.b.2.c.1-Change to importer,batch release arrangements and quality control testing of the FP - Replacementoradditionofamanufacturer responsible for importation and/or batch release - | 05/10/2021 | 29/09/2022 | Annex II and PL | Not includingbatch control/testing |
|           | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. C.1.11.z -Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation，includingtheRMP-Othervariation                                                                                                                                                                                                                   | 02/09/2021 | 11/10/2021 | Annex II        | WS/2109                            |
|           | This was an application for a group of variations. C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreedbythecompetentauthority C.1.11.a -Introduction of, or change(s) to, the                                                                                                                                                                                                     | 26/04/2021 | 11/10/2021 | Annex II        | IG/1383/G                          |

<div style=\"page-break-after: always\"></div>

|           | obligations and conditions of a marketing authorisation,including the RMP-Implementation of wordingagreedbythecompetent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     |           |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| WS/2041/G | Thiswasanapplicationforagroupofvariations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No 1234/2008. B.II.d.2.d -Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a-Change in test procedure for the finished product-Minorchangestoanapproved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 22/04/2021 | n/a | procedure |
|           | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. B.I.b.1.h -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl.Biol.orimmunol.substance)of a specification parameter as a result of a safety or quality issue                                                                                                                                                                                                                | 15/04/2021 | n/a | WS/2019   |

<div style=\"page-break-after: always\"></div>

| WS/2022/G   | This was an applicationfor a group ofvariations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.c-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specificationparametertothespecificationwith its corresponding test method B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitability tothe relevantPh.Eur.Monograph-Updatedcertificate from an already approved manufacturer   | 15/04/2021   | n/a        |                 |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|
| WS/2023/G   | This was an applicationfor a group ofvariations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.2.c.2-Change to importer,batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s)takeplace,exceptbatch-                                                                                                                                                                                                                                                                                                                                   | 25/03/2021   | 11/10/2021 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|          | release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.3.z-Change in the manufacturing process of thefinishedorintermediateproduct-Othervariation B.II.e.4.a - Change in shape or dimensions of the container or closure(immediate packaging)-Non- sterilemedicinal products                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |          |                                                                        |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------------------------------|
| A31/0098 | TheEuropeanCommissiontriggeredareferralunder Article31ofDirective2001/83/EC andrequestedthe CHMP to assess the impact of nitrosamine impurities on the benefit-risk balance of valsartan-containing medicinalproducts and to issue arecommendation on whether therelevantmarketing authorisations should be maintained,varied, suspended or revoked. During theCHMPplenarymeetinginSeptember 2018,thescopeof thereferral hasbeenwidened to include all sartans with a tetrazole group in their molecular structure (candesartan, irbesartan, losartan,olmesartan andvalsartan).The CHMP Opinionwasissuedon31January2019and the CommissionDecision was issued on 11April 2019. In aletterdated29July2020,theEuropean CommissionrequestedtheEMAtoassesstheimpact of theoutcomeof theArticle5(3)assessmenton nitrosaminesadoptedon25June2020on the CHMP'sopinionof31January2019forthescientific assessment and review under Article 31 of Directive 2001/83/EC regarding angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (EMEA/H/A-31/1471).The CHMP was requested to | 12/11/2020 | 19/02/2021 | Annex II | Pleasereferto the assessmentreport: ExforgeEMEA/H/A-31/1471/C/716/0098 |

<div style=\"page-break-after: always\"></div>

|         | the Marketing Authorisations shouldbevaried.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |          |           |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------|
| WS/1946 | Thiswasanapplicationforavariationfollowinga worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. B.II.b.3.z-Change in the manufacturing process of thefinishedorintermediateproduct-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                | 14/01/2021 | n/a        |          |           |
| IG/1319 | B.II.e.6.b -Change in any part of the (primary) packaging material not in contact with the finished productformulation-Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 07/12/2020 | n/a        |          |           |
|         | Thiswas anapplicationfor agroupofvariations. A.4-Administrative change-Change in the name and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateused in themanufacture of theASor manufacturer of a novel excipient B.I.a.1.f-Changein themanufacturerofASorofa startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacement or additionofasitewhere batch control/testing takes place B.I.b.1.h-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl.Biol.orimmunol.substance)ofa | 23/10/2020 | 11/10/2021 | Annex II | IB/0111/G |

<div style=\"page-break-after: always\"></div>

| specification parameter as a result of a safety or quality issue B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate- Other changestoatestprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.z-Change in test procedure forAS or starting material/reagent/intermediate - Other variation B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilityto the relevantPh.Eur.Monograph-Updatedcertificate from an already approved manufacturer B.II1.1.a.2-Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2-Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer B.Ill.1.a.3-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-New certificatefrom a newmanufacturer(replacement or addition)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IG/1254/G   | Thiswas an applicationfor a groupofvariations.                                                                                                                                                                                                                                                                                                                                                                                                                         | 15/05/2020   | n/a        |          |           |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------|-----------|
| IG/1174/G   | Thiswas anapplicationfor a group of variations. A.5.b-Administrative change -Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excludingmanufacturerforbatchrelease) A.7-Administrative change-Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangementsandqualitycontrol testingof theFP- Replacement/addition of a site where batch control/testingtakesplace | 11/12/2019   | n/a        |          |           |
|             | Thiswas anapplicationfor a group of variations. B.I.a.1.f-Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere                                                                                                                                                                                                                               | 27/09/2019   | 03/07/2020 | Annex II | IB/0108/G |

<div style=\"page-break-after: always\"></div>

| batch control/testing takes place B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltesting arrangementsfor the AS-replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batch control/testing takes place B.I.b.1.b-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl.Biol.orimmunol.substance)ofa specification parameter as a result of a safety or quality issue B.I.b.1.h-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.I.b.2.a-Change in testprocedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | variation                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                 |         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------|
| IG/1116/G | This was an applicationfor a group of variations. A.7-Administrativechange-Deletionof manufacturing sites B.II.b.1.a-Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1-Change to importer,batch release arrangementsandquality control testingof theFP- Replacementoradditionofamanufacturer responsible for importation and/or batch release - Not including batch control/testing | 16/07/2019 | 03/07/2020 | Annex II and PL |         |
| IG/1112   | C.1.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                | 05/07/2019 | n/a        |                 |         |
|           | A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                            | 24/05/2019 | n/a        |                 | IG/1100 |
| IG/1099   | A.7-Administrative change-Deletion of manufacturingsites                                                                                                                                                                                                                                                                                                                                                                             | 24/05/2019 | n/a        |                 |         |
| IG/1098   | B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updatedcertificate from an already approved manufacturer                                                                                                                                                                                                                                                          | 29/04/2019 | n/a        |                 |         |

<div style=\"page-break-after: always\"></div>

| IB/0102/G   | This was an applicationfor a group ofvariations.                                                                                                                                                                                                                                                                                                                                                                                         | 21/03/2019   | n/a        |                            |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------|
| IG/0986     | C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                    | 17/10/2018   | 11/04/2019 | Annex II, Labelling and PL |
| IG/0975/G   | Thiswas anapplicationfor a group of variations. B.I.a.1.f-Change in themanufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place B.Ill.1.a.1-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevant Ph.Eur.Monograph-New certificate from analreadyapprovedmanufacturer | 10/09/2018   | n/a        |                            |
| IG/0958/G   | Thiswas anapplicationfor a groupof variations. B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of                                                                                                                                                                                                                                                                                         | 21/08/2018   | n/a        |                            |

<div style=\"page-break-after: always\"></div>

|         | B.II.d.1.a - Change in the specification parameters and/or limits of thefinishedproduct-Tightening of specification limits B.II.d.1.a-Change in the specificationparameters and/or limits of thefinishedproduct-Tightening of specification limits B.II.d.1.c-Change in the specification parameters and/orlimitsof thefinishedproduct-Addition of a newspecificationparameter to thespecification with its corresponding test method   |            |            |                        | specification limits   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------|
| T/0096  | TransferofMarketingAuthorisation                                                                                                                                                                                                                                                                                                                                                                                                        | 16/05/2018 | 25/06/2018 | SmPC, Labelling and PL |                        |
|         | A.5.b-Administrative change-Change in the name and/oraddressof amanufacturer/importerof the finished product, including quality control sites (excluding manufacturer forbatchrelease)                                                                                                                                                                                                                                                  | 21/06/2018 | n/a        |                        | IG/0947                |
| IG/0910 | C.I.3.a - Change(s) in the SPC, Labelling or PL intended toimplementtheoutcomeofaprocedure concermingPSURorPASSortheoutcomeofthe assessment done under A 45/46 -Implementation of wording agreed by the competent authority                                                                                                                                                                                                             | 17/04/2018 | 25/06/2018 | SmPC and PL            |                        |
|         | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No                                                                                                                                                                                                                                                                                            | 15/03/2018 | n/a        |                        | WS/1291/G 1234/2008.   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.2.b-Change in test procedure for AS or starting material/reagent/intermediate -Deletion of a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.b -Change in test procedure forAS or startingmaterial/reagent/intermediate-Deletionof a testprocedurefortheASorastarting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.b-Change in testprocedure forAS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.b-Change in testprocedure forAS or startingmaterial/reagent/intermediate-Deletionof a testprocedurefortheASorastarting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.b -Change in test procedure forAS or   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | a testprocedurefortheASorastarting material/reagent/intermediate,if an alternativetest procedure is already authorised B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate -Deletion of a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate   |            |     |                                |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------|
| IG/0863             | A.4-Administrative change-Changein thename and/oraddressof amanufactureror anASMFholder orsupplieroftheAS,startingmaterial,reagentor intermediateused in themanufactureof theASor manufacturerofanovelexcipient                                                                                                                                                                                                                                                                                                                                              | 01/12/2017 | n/a |                                |
| IG/0805             | A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 23/05/2017 | n/a |                                |
| PSUSA/10344 /201606 | PeriodicSafetyUpdateEUSingleassessment- amlodipine/valsartan,amlodipine/ hydrochlorothiazide/valsartan                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 09/03/2017 | n/a | PRACRecommendation-maintenance |
| IG/0776             | B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilityto the relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                | 23/02/2017 | n/a |                                |

<div style=\"page-break-after: always\"></div>

| WS/1080   | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 23/02/2017   | 08/02/2018   | SmPC and PL   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|
| IG/0751/G | Thiswas an applicationfor a group of variations. A.7-Administrativechange-Deletion of manufacturingsites A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrativechange-Deletionof manufacturingsites                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 15/12/2016   | n/a          |               |
| IG/0727/G | This was an application for a group of variations. B.I.a.1.f -Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place B.1.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.1.b.2.a-Change in testprocedure forAS or | 14/09/2016   | n/a          |               |

<div style=\"page-break-after: always\"></div>

|         | startingmaterial/reagent/intermediate-Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0707 | B.I.a.1.f -Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 21/07/2016 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IG/0706 | B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 21/07/2016 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| WS/0709 | Thiswas an applicationfor avariationfollowing a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. Changesrelated tothe amlodipine component Updateofsection4.2of theSmPCtoincluderevised dosingrecommendationsinpatientswithhepatic impairment and in elderly patients. Changesrelatedtothevalsartancomponent Updateofsections4.2and4.3of theSmPCto remove thecontraindicationrelated topatientswith severe renal impairment and patients undergoing dialysisandsection4.8of theSmPCtoupdate the PreferredTerm asperMedDRAversion17. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implementminoreditorial changesintheSmPC and thePackageLeaflet | 26/03/2015 | 05/05/2015 | SmPC and PL | Theremovalof thecontraindicationrelated topatientswith severe renal impairment and patients undergoing dialysis, iseditorial innature andisimplementedtoalign the product information with the decision from Article 30 Referralprocedure(EMEAprocedurenumber:EMEA/H/A- 30/998) concluded for Diovan in Nov 2008.As an oversight, thiswasnot applied totheExforgeproduct informationatthetime. Theposologysectionis updated tohighlightthatwhen switchingeligiblehypertensivepatientswithhepatic impairmentor elderlyhypertensivepatientsto amlodipine or Exforge, the lowest available dose of amlodipine monotherapyor of the amlodipine component,respectively, should be used. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IG/0539   | C.I.1.a - Change(s) in the SPC, Labelling or PL intended toimplementtheoutcomeof aUnion referral procedure - The product is not covered by thedefinedscopeoftheprocedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 27/03/2015 | 22/03/2016 | SmPC and PL |
| IG/0536/G | Thiswasanapplicationforagroupofvariations. B.I.b.1.c-Change in thespecificationparameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.d-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Deletionofanon- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a -Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitability to the relevant Ph. Eur. Monograph - Updated certificate fromanalreadyapprovedmanufacturer | 11/03/2015 | n/a        |             |

<div style=\"page-break-after: always\"></div>

|           | B.IIl.1.a.2-Submissionofanew/updatedor deletion of Ph. Eur. Certificate of Suitability to the relevant Ph.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |                           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------|
| IG/0528/G | This was an application for a group of variations. A.4-Administrative change-Change in thename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateused in themanufactureof theASor manufacturerofanovelexcipient B.1.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparametertothe specificationwith its | 17/02/2015 | n/a | corresponding test method |
| IG/0523/G | This was an application for a group of variations. A.5.b-Administrativechange-Changeinthename and/oraddressofamanufacturer/importerofthe finished product, including quality control sites (excludingmanufacturerforbatchrelease) A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                                                                                                                                                              | 22/01/2015 | n/a |                           |

<div style=\"page-break-after: always\"></div>

| IG/0514   | A.1-Administrative change -Change in the name and/oraddressoftheMAH                                                                                                                                       | 16/12/2014   | 05/05/2015   | SmPC, Labelling and PL   |                                                                           |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------------------------------------------------------------|
| WS/0632/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To implement changes in the manufacturing process | 23/10/2014   | n/a          |                          | To implement changes in the manufacturing process of the active substance |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.I.a.4.z-Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its correspondingtestmethod                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/0630/G | Thiswas anapplicationfor agroupofvariations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. Replacementof2 testmethodsfor anactive substance intermediate. To incude a minor change in a test method for an activesubstanceintermediate. To add3testmethodsfor anactivesubstance intermediate. Tochange thespecificationparameterfor anactive substanceintermediate. B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoatestprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure | 23/10/2014 | n/a |

<div style=\"page-break-after: always\"></div>

|           | and/or limits of an AS, starting material/intermediate/reagent-Additionof anew specification parameter to the specification with its corresponding test method B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.2.e-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwithits corresponding test method B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its correspondingtestmethod   |            |     |                                                                                                                                                                                                                                                                     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0629/G | Thiswas an applicationfor agroupofvariations followingaworksharingprocedureaccordingto Article20of CommissionRegulation(EC)No 1234/2008. Toreplace3 testmethodsfor anactive substance intermediate. To include a minor change to an approved test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 23/10/2014 | n/a | Toreplace3testmethodsforanactivesubstance intermediate. Toincludeaminorchangetoanapproved testprocedure foranactivesusbatcneintermediate. To add a testmethod or an activesubstanceintermediate. To add2alternative testmethodsforan active substance intermediate. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| procedure for an active susbtance intermediate. To add a test methodor an active substance intermediate. Toadd2 alternativetestmethodsfor anactive substance intermediate. B.I.b.2.e-Change in test procedure forAS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e-Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or starting material/reagent/intermediate - Other changesto a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.a-Change in test procedure forAS or starting material/reagent/intermediate - Minor changestoanapprovedtestprocedure B.I.b.1.c -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparameter to thespecificationwithits corresponding test method B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | specification parameter to the specification with its corresponding test method B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent -Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                        |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------|
| WS/0631/G | Thiswas an applicationfor a groupofvariations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Toadd an alternativemanufacturer of AS intermediates. ToincreasethebatchsizesforASintermediatesfor the new manufacturing site To delete a manufacturing siteforASintermediates. B.I.a.1.z-Change in the manufacturer ofASor of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a-Change inbatch size(including batch size ranges)ofASorintermediate-Up to10-fold increase compared to the originally approved batch size A.7-Administrativechange-Deletionof manufacturing sites | 23/10/2014 | n/a        |             |                                                                                                        |
| A31/0067  | On17April2013,furthertotheemergenceofnew evidencefromthescientificliteratureondualRAS blockade therapy and given the seriousness of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 22/05/2014 | 04/09/2014 | SmPC and PL | ForfurtherinformationpleaserefertotheRenin- angiotensin-system (RAS)-acting agents Article 31 referral |

<div style=\"page-break-after: always\"></div>

|           | identified safety concerns, the Italian Medicines Agency (AIFA) initiated a review under Article 31 of Council Directive 2001/83/EC, requesting the PharmacovigilanceRiskAssessmentCommittee (PRAC)toissue arecommendationonthebenefit- risk of dual RASblockade therapy through the combined use of angiotensin-converting enzyme inhibitors (ACE-inhibitors), angiotensin II receptor blockers(ARBs)or aliskiren and todetermine whether any regulatory measures should be taken on themarketing authorisations of theproducts involved in this procedure.   |            |            |      | - Assessment report.                                                                                                                                                                                                                                              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0424/G | This was an applicationfor a group ofvariations. A.7 - Administrative change - Deletion of manufacturing sites A.7-Administrativechange-Deletionof manufacturing sites B.I.a.1.f-Changein themanufacturer of ASor of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltesting arrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place                                                                                                                                                                    | 26/03/2014 | n/a        |      |                                                                                                                                                                                                                                                                   |
| WS/0516   | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Updateofsection4.8oftheSmPCtoincludethe                                                                                                                                                                                                                                                                                                                                                                                    | 20/03/2014 | 04/09/2014 | SmPC | TheMAHhassubmittedacomprehensivereportwiththe purpose of reviewing the potential association of skin events with valsartan containing medications, including Exforge andExforgeHCTandrespectiveclones.It is consideredjustified toupdatethelistofADRsinsection4.8 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | ADR'bullous dermatitis'. C.I.4 - Change(s) in the SPC, Labelling or PL due to newquality,preclinical,clinical orpharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     | undesirableeffects'of theExforgeSmPC andExforgeHCT SmPC and their respective clones based on additional informationfrom asmall numberofpost-marketingcases reportingbullousrash occurringwithvalsartan.This amendmentdoesnotchangethebenefitriskbalancefor theseproductswhichremainspositive.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0495/G | Thiswasan applicationfor a group of variations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No 1234/2008. -changeinthespecificationlimitsofsome intermediatesusedinthemanufactureoftheactive substance, - addition of a new specification parameters with theircorrespondingtestmethodstothespecification ofsomeintermediatesused in themanufactureof the active substance and - change in test procedures for some intermediates used in themanufacture of the activesubstance. B.1.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.1.c-Change in thespecificationparameters | 20/02/2014 | n/a |                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e-Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in testprocedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in testprocedure forAS or starting material/reagent/intermediate- Other changes to a testprocedure(includingreplacement   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | material/intermediate B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method                                                                                                                                                                             |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0377/G | Thiswas an applicationfor a group of variations. B.I.b.1.b -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its correspondingtestmethod | 22/11/2013 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| WS/0461   | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. Updateofsection4.5of theSmPCtoincludefurther informationregardinganinteractionbetween valsartan and lithium. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                             | 21/11/2013 | 04/09/2014 | SmPC | TheMAHhasreviewedtheclinicaldatabasesoffourlarge outcomes studies (Val-HeFT, Value, Valiant, and Navigator) for adverse event reports of lithium toxicity.Further, the NovartisSafetyDatabase(ARGUS)wassearchedforall caseswherebothvalsartanandlithiumwerereported as co-administered,andaliteraturesearchwasperformedfor published studies. The available data suggest a possible reversible interaction betweenvalsartan andlithium,although theexact mechanismhas notbeen established.The data identified arelimited andnoconfirmatoryevidencewas available from the clinical trials performed. TheSmPChasbeenupdatedtoinformprescribersof the |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                       | fact thatreversibleincreases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonistsincluding valsartan.Therefore,careful monitoringofserumlithiumconcentrationsis recommendedduringconcomitantuse.Ifadiurecticis also used, the risk of lithium toxicity may presumably be increased further.   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0349 | B.Ill.1.a.4-Submissionofanew/updatedor deletion ofPh.Eur.Certificateof Suitability tothe relevantPh.Eur.Monograph-Deletion of certificates (incasemultiplecertificatesexistpermaterial)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 27/08/2013 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                |
| WS/0360 | Thiswasanapplicationforavariationfollowinga worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Update ofSmPC sections 4.2,4.3,4.4 and 4.5 to reflect that the concomitant use of Angiotensin II Receptor Blockers (ARBs) or Angiotensin-Converting- Enzyme inhibitors (ACEi) with aliskiren is contraindicated in patients with renal impairment and in patients with diabetes mellitus.Further, section4.4oftheSmPChasbeenupdated toinform prescribers that caution is required, and monitoring of blood pressure, renal function and electrolytes is recommended, when co-administering agents acting onthereninangiotensinaldosteronesystem(RAAS) i.e.ACEi, ARBs or aliskiren as a direct renin inhibitor. The Package Leaflet has been updated accordingly. | 27/06/2013 | 31/07/2013 | SmPC, Annex II and PL | Please refer to the Scientific Discussion\"Exforge-Copalia- Dafiro-Imprida-EMEA-H-C-xxxx-WS-360-AR\".                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | theSmPC,Annex II and thePackageLeafletinline withthelatestQRDtemplate,toimplementminor editorial changesinthePackageLeaflet and toadd thecontactdetailsoftheCroatianlocal representative in the Package Leaflet. C.I.4-Variationsrelated tosignificantmodifications of theSPCdue inparticular to newquality,pre- clinical, clinical or pharmacovigilance data   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0270   | B.I.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits                                                                                                                                                                                                                | 01/02/2013 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                        |
| IG/0248   | C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                       | 17/12/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                        |
| IG/0233   | B.III.1.a.2-Submission of a new or updated Ph.Eur. Certificate of Suitability to the relevantPh.Eur. Monograph-Updatedcertificatefrom analready approved manufacturer                                                                                                                                                                                           | 13/11/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                        |
| WS/0249/G | Thiswas an applicationfor agroupofvariations followingaworksharingprocedure according to Article 20 of Commission Regulation (EC) No 1234/2008. WS-0249-Gwasagroupofvariationsconsisting of twoTypeII variationsfollowing aworksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008 as follows:                                 | 20/09/2012 | 29/10/2012 | SmPC and PL | The safety update of the SmPC and Package Leaflet was based on a review of the MAH's safety and clinical trial data bases,published literatureforboththeamlodipine and valsartancomponents,arecommendationbytheUSFDA aswell astherecentrevisedandharmonisedamlodipine CHMPaspartofthearticle30referralprocedure EMEA/H/A-30/1288on21July2011. TheMAHpresentedanextensiveanalysisofboth |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |            | ThesafetydataprovidedbytheMAH isregarded as sufficient in order to justify the proposed warning on angioedema'insection4.4of theSmPC.It shouldalsobe notedthatawarningregarding'angioedema'isalready included in the SmPC for Diovan (valsartan monotherapy). Additionalchangestothewordingofwarningsalready included inSmPCsection4.4(\"renal arterystenosis\", \"heartfailure”and\"aorticandmitral valvestenosis\")were alsomadeaspartof thisprocedure inordertoprovide further clarity to thehealth careprofessional. Inaddition,theMAHtooktheopportunity toupdatethe amlodipinesectionsoftheSmPCinaccordancewiththe harmonisedproductinformationforNorvasc(amlodipine monotherapy).                                                                                                                                                                  |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0248/G | Thiswasanapplicationforagroupofvariations followingaworksharingprocedureaccording to Article20ofCommissionRegulation(EC)No 1234/2008. WS-0248-G was a group of variations consisting of two Type II variations following a worksharing procedure according toArticle 20of Commission Regulation(EC)No1234/2008asfollows: Variation1:Updateofsection4.5oftheSmPCto add information about thepotential druginteraction betweenamlodipineandsimvastatin,，andupdateof theexisting amlodipineinformation insection 4.5 in line with the revised drug interactions section for Norvasc(amlodipine monotherapy).ThePackage Leaflet has been updated accordingly; Variation2:Updateof section4.5of theSmPC to | 19/07/2012 | 30/08/2012 | SmPC andPL | Administrationof amlodipinewithgrapefruit orgrapefruit juiceisnotrecommendedasbioavailabilitymaybe increased in some patients, resulting in increased blood pressure lowering effects. Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors(protease inhibitors,azole antifungals, macrolides likeerythromycin or clarithromycin,verapamil ordiltiazem)maygiverise tosignificantincrease in amlodipine exposure. The clinical translation of these pharmacokineticvariationsmaybemorepronouncedinthe elderly.Clinical monitoring and dose adjustment may thus be required. ThereisnodataavailableregardingtheeffectofCYP3A4 inducersonamlodipine.TheconcomitantuseofCYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give alowerplasma concentrationofamlodipine.Amlodipine shouldbeusedwithcautiontogetherwithCYP3A4 |

<div style=\"page-break-after: always\"></div>

|           | addinformation aboutthepotentialdruginteraction betweenvalsartanandinhibitorsof theuptake transporter(rifampicin, ciclosporin) orefflux transporter(ritonavir).ThePackageLeaflet hasbeen updated accordingly. C.I.4-Variationsrelated tosignificantmodifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data C.I.4-Variationsrelatedtosignificantmodifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |            |     | inducers. Co-administration of multiple doses of 10 mg amlodipine with80mgsimvastatinresultedina77%increasein exposuretosimvastatincompared tosimvastatin alone.It is recommended to limit the dose of simvastatin to 20 mg daily inpatients on amlodipine. In animals,lethalventricular fibrillation and cardiovascular collapseareobservedinassociationwithhyperkalaemia after administration of verapamil and intravenous dantrolene.Due to riskofhyperkalaemia,it is recommended that the co-administration of calcium channelblockerssuchasamlodipinebeavoidedinpatients susceptibletomalignanthyperthermiaandinthe managementofmalignanthyperthermia. In clinical interaction studies,amlodipine did not affect the pharmacokineticsofatorvastatin,digoxin,warfarin or ciclosporin. The results of an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporterOATPiB1andofthehepaticeffluxtransporter MRP2.Co-administration ofinhibitors of theuptake transporter(rifampicin,ciclosporin)oreffluxtransporter (ritonavir) may increase the systemic exposure to   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0209/G | This was an application for a group of variations. C.I.9.b-Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h-Changes to an existingpharmacovigilance system as described in the DDPS - Other change(s)                                                                                                                                                                                                                                  | 17/08/2012 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|           | totheDDPSthatdoesnotimpactontheoperationof the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                           |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|
| WS/0282   | Thiswasanapplicationforavariationfollowinga worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. toadd a newspecificationparameterforimpurities in the active substance. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its                                                                                                                                                                                                                                                                                            | 19/07/2012 | 19/07/2012 | corresponding test method |
| IG/0199/G | This was an application for a group of variations. B.I.a.1.f -Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place A.5.b-Administrative change -Change in the name and/oraddressof amanufacturerof thefinished product, including quality control sites (excluding manufacturerforbatchrelease) | 09/07/2012 | n/a        |                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.III.1.a.2-Submission of a new or updated Ph.Eur. Certificate of Suitability to therelevantPh.Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0251/G | This was an application for a group of variations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. WS-0251-G is a group of twovariations(one type II &onetypeIB)followingaworksharingprocedure as follows: -Type IIvariation:Update of section 4.6 of the SmPCwithwording onfertility in line withtheSmPC forDiovan(valsartanmonotherapy)and5.3of the SmPCtoimplementthechangestotheSmPCfor Diovan that was approved as part of a recent Article 30 (referral) procedure; - Type IB variation: Update of sections 4.6 and 5.3 of theSmPCtoimplementthechangesto theSmPCfor Norvasc(amlodipine monotherapy)that was approved as part of a recent Article 30 (referral) procedure. C.I.1.b - Change in the SPC, Labelling or PL following a referral procedure-Theproduct isnot covered by the defined scope of the referral but the change implementstheoutcomeof thereferral andnonew additional data aresubmittedby theMAH C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation | 24/05/2012 | 28/06/2012 | SmPC | The safety of amlodipine in human pregnancy has not been established. Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labouranddecreasedpupsurvival atdosages approximately 50 times greater than the maximum recommended dosage forhumans based on mg/kg.Use in pregnancy is only recommended when there is no safer alternativeandwhenthediseaseitselfcarriesgreaterrisk for the mother and foetus. Reversiblebiochemicalchangesintheheadofspermatozoa havebeenreported insomepatientstreatedbycalcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. There was no effectonthefertilityofratstreatedwithamlodipine(males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis). In another rat studyinwhichmaleratsweretreatedwithamlodipine besilatefor30daysatadosecomparablewiththehuman dose based on mg/kg, decreased plasma follicle-stimulating hormoneandtestosteronewerefoundaswellasdecreases inspermdensityandinthenumberofmaturespermatids and Sertoli cells. Rats andmice treated with amlodipinein the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, |

<div style=\"page-break-after: always\"></div>

| andforratstwice*themaximumrecommendedclinical doseof10mgonamg/m2basis)wasclosetothe maximum tolerated doseformicebut notforrats. Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.  * Based on patient weight of 50 kg  Valsartanhadnoadverseeffectsonthereproductive  performance of male or female rats at oral doses up to 200  mg/kg/day. This dose is 6 times the maximum  recommendedhumandoseonamg/m2basis(calculations  assume an oral dose of 320 mg/day and a 60-kg patient).  Non-clinical data reveal no special hazard for humans  based on conventional studies of safety pharmacology,  repeated dose toxicity, genotoxicity, carcinogenic potential.  Inrats,maternallytoxicdoses(600mg/kg/day)during the  last days of gestation and lactation led to lower survival,  lower weight gain and delayed development (pinna  detachment and ear-canal opening) in the offspring (see  section 4.6).These doses in rats (600 mg/kg/day)are  approximately 18 times the maximum recommended  humandoseonamg/m2basis(calculationsassume an  oral dose of 320 mg/day and a 60-kg patient).  In non-clinical safety studies,high doses of valsartan(200  to600mg/kgbodyweight)caused inrats areductionof  redblood cellparameters(erythrocytes,haemoglobin,  haematocrit)andevidenceofchangesinrenal  haemodynamics(slightlyraisedplasmaurea,andrenal  tubularhyperplasia andbasophilia inmales).These doses  in rats (200 and 600 mg/kg/day) are approximately 6 and  18timesthemaximumrecommendedhumandoseona  mg/m2 basis (calculations assume an oral dose of 320  mg/day and a 60-kgpatient).   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                                  | Inmarmosetsatsimilardoses,thechangesweresimilar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised ureaand creatinine. Hypertrophyoftherenaljuxtaglomerularcellswasalso seeninbothspecies.Allchangeswereconsideredtobe caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem tohave any relevance.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0148/G | This was an applicationfor a group ofvariations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the majorcontractualarrangementswithotherpersons or organisationsinvolvedinthefulfilment of pharmacovigilance obligations anddescribedinthe DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS -Other change(s) to the DDPS that does not impact on the operation of thepharmacovigilancesystem | 22/02/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| R/0048    | Renewal of themarketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                              | 22/09/2011 | 22/11/2011 | SmPC, Annex II, Labelling and PL | BasedontheCHMPreviewoftheavailableinformationand on the basis of a re-evaluation of the benefit risk balance, the CHMP was of the opinion that the quality, safety and efficacyofthismedicinalproductcontinuestobe adequatelyandsufficientlydemonstratedandtherefore consideredthatthebenefitriskprofileofImpridacontinues tobefavourable.                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             | The CHMP recommended the renewal of the Marketing AuthorisationforImprida,subject to the conditions as laid down in Annex II to the Opinion. The CHMP was also of the opinion that the renewal can be granted with unlimited validity. Therenewalrequiredamendmentstothetermsofthe CommunityMarketingAuthorisationbasedon theCHMP's request to implement the latest QRD template. Therefore, theCHMPrecommendedthefollowingannexestobe amended: I, II, IIIA and IIIB.                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0100/G | Thiswas an applicationfor a group ofvariations followingaworksharingprocedureaccordingto Article20ofCommissionRegulation(EC)No 1234/2008. UpdateofSummaryofProductCharacteristicsand PackageLeaflet Thiswas an applicationfor agroupofvariations followingaworksharingprocedureaccordingto Article20ofCommissionRegulation(EC)No 1234/2008. C.I.4-Variations related to significant modifications of theSummary ofProduct Characteristics duein particular to new quality, pre-clinical, clinical or pharmacovigilance data C.I.4-Variationsrelatedto significant modifications of the SPC due in particular to new quality, pre- | 23/06/2011 | 27/07/2011 | SmPC and PL | WS-0100-Gwassubmittedforagroupofvariations consisting of threeTypeIIvariationsfollowinga worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. Thefollowingvariationwasnotconsideredacceptableby the CHMP: - Variation 1 (scope as applied for by the MAH): Update of section5.1of theSmPCwithinformationonefficacy in patients with stage 2 hypertension and black patients basedonstudiesVAA2402andVAA2403. Thefollowingvariationswereconsideredacceptablebythe CHMP: -Variation2:Deletionof thecurrentparagraphinsection 5.1oftheSmPCthatprovidesinformationontherelative efficacyofvalsartan/amlodipine80/5mgcomparedto amlodipine10mg inrelationtotheincidence of oedema.In addition,theMAH tooktheopportunitytoupdatetheSmPC inlinewiththelatestQRDtemplateandtoupdatethe contactdetailsofthelocalrepresentativesinthePackage |

<div style=\"page-break-after: always\"></div>

|           | clinical, clinical or pharmacovigilance data C.I.4-Variations related to significant modifications of theSPC dueinparticular tonewquality,pre- clinical, clinical or pharmacovigilance data C.I.4-Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                 |            |     | Leaflet. -Variation3:Update of section5.1 of theSmPCwith information onefficacy in obesepatients. [crossreference toScientificdiscussionofadoptedCHMP Assessment Report].   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0088/G | This was an application for a group of variations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisationsinvolved inthefulfilment of pharmacovigilanceobligations anddescribedinthe DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of | 11/07/2011 | n/a |                                                                                                                                                                             |
| IG/0074/G | This was an application for a group of variations. B.I.a.2.a-Changes in the manufacturing process of theAS-Minor changeinthemanufacturingprocess of theAS B.I.b.1.c-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.1.b.1.c-Changein the specification parameters                                          | 17/06/2011 | n/a |                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure B.I.b.2.a-Change in test procedure forAS or starting material/reagent/intermediate - Minor changes to an approved test procedure   |            |            |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| IG/0058   | B.III.1.a.2-Submission of a new or updated Ph.Eur. Certificate of Suitability to the relevantPh.Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13/04/2011 | n/a        |
| WS/0088/G | Thiswasanapplicationforagroupofvariations followingaworksharingprocedureaccording to Article20of CommissionRegulation(EC)No 1234/2008. to change the specification limit for an impurity in the active substance ; toaddnewtestproceduresfortheactivesubstance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 17/02/2011 | 17/02/2011 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| toaddnewspecificationsin theactivesubstance todelete a testprocedureforthe active substance. B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.b-Change in test procedure for AS or startingmaterial/reagent/intermediate-Deletionof a testprocedurefortheASorastarting material/reagent/intermediate,if analternativetest procedure is already authorised B.I.b.2.e-Change in test procedure forAS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IG/0032/G   | This was an applicationfor a group ofvariations.                                               | 21/12/2010   | n/a   | Annex II   |
|-------------|------------------------------------------------------------------------------------------------|--------------|-------|------------|
| IG/0028     | B.II.b.1.a-Replacement or addition of a manufacturing site for the FP-Secondary packaging site | 12/11/2010   | n/a   |            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0047/G   | This was an applicationfor a group of variations.   | 24/06/2010   | n/a   |
|-------------|-----------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

|           | specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                        |                                                |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------|
| IA/0046/G | This was an applicationfor a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1-Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within therangeofthecurrentlyapprovedpacksizes B.II.e.5.a.1-Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within | 25/05/2010 | 25/05/2010 | SmPC, Labelling and PL | the range of the currently approved pack sizes |
|           | Changes to QPPV UpdateofDDPS(Pharmacovigilance)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 18/02/2010 | 23/03/2010 | Annex II               | II/0045                                        |
| II/0041   | Change in the manufacturing process of the drug substanceValsartan;addition of an alternative process for the synthesis of one of the compound used. Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                             | 19/11/2009 | 02/12/2009 |                        |                                                |
| IA/0043   | IA_07_b_01_Replacement/add. of manufacturing site:Primarypackagingsite-Solidforms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 27/11/2009 | n/a        |                        |                                                |
| IA/0044   | IA_O7_a_Replacement/add.of manufacturing site: Secondarypackaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 25/11/2009 | n/a        |                        |                                                |

<div style=\"page-break-after: always\"></div>

| IB/0042   | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                                                                                                                                                | 24/11/2009   | n/a        | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0037   | To tighthen thespecification,modifytestprocedures and introducenewonesfortheactivesubstance valsartan in order to update theTestingMonograph of valsartan. Quality changes                                                                                                                                                                                                | 24/09/2009   | 07/10/2009 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0040   | IA_11_a_Change inbatch size of active substance or intermediate-upto10-fold                                                                                                                                                                                                                                                                                               | 17/08/2009   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0039   | IA_04_Change in name and/or address of a manuf. of theactive substance(noPh.Eur.cert.avail.)                                                                                                                                                                                                                                                                              | 28/07/2009   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0038   | IA_o9_Deletionofmanufacturingsite                                                                                                                                                                                                                                                                                                                                         | 28/07/2009   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0034   | TheMAHappliedforanupdateoftheSPCsection 4.6aswell asPLsection2 toimplement theCHMP recommendation on a harmonised labelling relating to the use of Angiotensin II Receptor Antagonists during pregnancy and lactation. Furthermore, minor typographical changes have been introduced to SPC sections4.3and4.4. UpdateofSummaryofProductCharacteristicsand Package Leaflet | 19/02/2009   | 27/03/2009 | SmPC and PL | AvailabledataregardinguseofAIIRAsduringlactation havebeen assessed.There are no concrete data to support the contraindication of use of AlIRAs during breast-feeding. AllAlIRAagentswerefound in themilkoflactatingratsbut nohumandata about theirtransferintobreastmilkare available.Thereisonlya theoreticalpresumptionof low transport according to their high plasma protein binding and low oral availability. A harmonised wording recommendinganaltermativetreatmentwithbetter established safety profiles during breast-feeding, especially while nursing a newborn or preterm infant,hasbeen |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                               |            |            |             | PL.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0036 | IB_14_b_Change in manuf.of active substance withoutPh.Eur.certificate-newmanufacturer                                                                                                                                                                                                         | 13/03/2009 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0035 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                            | 24/02/2009 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0030 | UpdateofSPCsection4.8andPLsection4regarding the safety information presented for the individual components of the combination product. In addition, the MAH took the opportunity to update the list of local representatives. Update of Summary of Product Characteristics and PackageLeaflet | 18/12/2008 | 13/02/2009 | SmPC and PL | Followingtheassessmentofthe2ndPSUR theCHMP) requested the addition of the terms \"myocardial infarction\" and \"arrhythmia\" to SPC section 4.8 with the frequency \"not known\" because several cases were received during the reporting period of the PSUR and these Adverse Drug Reactions are also seen in connection to the treatment with amlopdipine. Furthermore, additional information regarding the potential decreasesinhaematocritandhaemoglobinlevelsforthe individual component valsartan was included based on a review which revealed that the information on laboratory evaluation is not in line with monotherapySPC. ThePackageLeaflethasbeenupdatedtoensure consistencywithsection4.8of theSPC. |
| IB/0031 | IB_14_b_Changeinmanuf.ofactivesubstance withoutPh.Eur.certificate-newmanufacturer                                                                                                                                                                                                             | 31/10/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0033 | IA_11_a_Change inbatch size of active substance or intermediate - up to 10-fold                                                                                                                                                                                                               | 23/10/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0032 | IA_11_a_Changeinbatch size of active substance or intermediate-upto10-fold                                                                                                                                                                                                                    | 23/10/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IB/0029   | IB_33_Minorchangeinthemanufactureof the finished product                                                                                                                                                                                                                                                         | 25/07/2008   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0028   | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site IB_07_c_Replacement/add.of manufacturing site: Allothermanufacturingoperationsex.batchrelease                                                                                                                                         | 23/07/2008   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0027   | IA_07_a_Replacement/add.of manufacturing site: Secondarypackagingsite IA_o7_b_01_Replacement/add.ofmanufacturing site:Primarypackagingsite-Solidforms                                                                                                                                                            | 10/07/2008   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0026   | IA_32_a_Change inbatchsize of thefinishedproduct - up to 10-fold                                                                                                                                                                                                                                                 | 07/07/2008   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0024   | IB_12_b_02_Change in spec.of active subst./agent in manuf.ofactive subst.-testparameter                                                                                                                                                                                                                          | 03/07/2008   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0025   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph.Eur.cert.avail.)                                                                                                                                                                                                                  | 24/06/2008   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0019   | TheMAH appliedfor anupdateof theSPCsections 4.3, 4.4, and 4.6 as well as PL section 2 to implementtheCHMPrecommendationona harmonised labelling relating to the use of ACE inhibitors and Angiotensin II Receptor Antagonists during pregnancy. Update of Summary of Product Characteristics and Package Leaflet | 24/04/2008   | 10/06/2008 | SmPC and PL | Cooper's studypublished intheNEJMinJune2006 identifiedasignal ofincreasedriskofcongenital malformations,particularlycardiacdefectsafterexposure to ACE inhibitors during the first trimester of pregnancy. Since the role of confounding factors such as diabetes and hypertension cannot be accurately defined based on the available data, the teratogenic potential of ACE inhibitors is notdemonstrated,eventhoughdatasuggestthatsuch exposure cannot be considered as safe and should be avoided. |

<div style=\"page-break-after: always\"></div>

|         |                                                                                         |            |            |                        | There arefewerdataregarding therisks associatedwith firsttrimesterexposuretoAngiotensinIIreceptor antagonists(AIIRAs) than forACE inhibitors.Nevertheless, there is no evidence that the riskis lowerforAIIRAs,and it is consideredthat anyconclusions onACEinhibitors are also valid for AIIRAs. Therefore, the existing contraindication for the 9-month pregnancy was revised in order to delete the contraindication during the 1st trimester of pregnancy, but toremain thecontraindicationfor the2nd and3rd trimester of pregnancy. In addition, a harmonised wording regardingpregnancy acrossthe classwasintroduced.   |
|---------|-----------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0023 | IA_15_a_Submission ofPh.Eur.certificate for active substance-approved manufacturer      | 29/05/2008 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0022 | IA_41_a_01_Change in pack size - change in no. of units within range of appr.pack size  | 06/05/2008 | 06/05/2008 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0021 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size | 06/05/2008 | 06/05/2008 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0020 | IA_41_a_01_Change in pack size -change in no. of unitswithinrangeof appr.pack size      | 06/05/2008 | 06/05/2008 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IB/0017 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale              | 10/12/2007 | n/a        | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0016 | IA_o7_a_Replacement/add.ofmanufacturingsite: Secondary packaging site                   | 19/09/2007 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|         | IA_07_b_01_Replacement/add.ofmanufacturing site: Primary packaging site - Solid forms   |            |            |                        |         |
|---------|-----------------------------------------------------------------------------------------|------------|------------|------------------------|---------|
|         | IA_41_a_01_Change in pack size - change in no. of unitswithinrange of appr.pack size    | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL | IA/0015 |
| IA/0014 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0013 | IA_41_a_01_Change in pack size - change in no. of units within range of appr.pack size  | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0012 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0011 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0010 | IA_41_a_01_Change in pack size - change in no. of units withinrange of appr.pack size   | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0009 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0008 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |

<div style=\"page-break-after: always\"></div>

| IA/0007   | IA_41_a_01_Change in pack size -change in no.of units within range of appr. pack size   | 13/09/2007   | 13/09/2007   | SmPC, Labelling and PL   |         |
|-----------|-----------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------|
| IB/0006   | IB_14_b_Change in manuf.of active substance without Ph.Eur.certificate-new manufacturer | 13/07/2007   | n/a          |                          |         |
|           | IA_15_a_Submission ofPh.Eur.certificate for active substance-approvedmanufacturer       | 27/04/2007   | n/a          |                          | IA/0004 |
|           | IA_11_a_Change in batch size of active substance or intermediate-upto10-fold            | 02/04/2007   | n/a          |                          | IA/0003 |
| IA/0002   | IA_11_a_Change inbatch size of active substance or intermediate - up to 10-fold         | 02/04/2007   | n/a          |                          |         |
| IA/0001   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold        | 02/04/2007   | n/a          |                          |         |